Enveric Biosciences (ENVB) Treasury Shares (2015 - 2024)
Enveric Biosciences (ENVB) posted Treasury Shares of $351616.0 for Q3 2024, down 1.26% sequentially from $356116.0 in Q2 2024, and up 137.18% YoY from $148251.0 in Q4 2023.
Enveric Biosciences (ENVB) Treasury Shares (2015 - 2024) Analysis & Trends
Enveric Biosciences has reported Treasury Shares for 7 years, with the latest figure at $351616.0 in Q3 2024.
- Quarterly Treasury Shares rose 137.18% year-over-year to $351616.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $351616.0 (up 137.18% YoY) and the FY2022 annual result came in at $4271.0, down 93.11% from the prior year.
- Treasury Shares fell to $351616.0 in Q3 2024 per ENVB's latest filing, from $356116.0 in the prior quarter.
- Over five years, Treasury Shares peaked at $4.8 million in Q1 2022 and troughed at $6652.0 in Q3 2021.
- A 4-year average of $855956.4 and a median of $180115.0 in 2023 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2022 and 2023: Treasury Shares soared 878.91% in 2022, then tumbled 98.17% in 2023.
- Over 4 years, Treasury Shares stood at $62013.0 in 2021, then gained by 5.01% to $65117.0 in 2022, then surged by 127.67% to $148251.0 in 2023, then surged by 137.18% to $351616.0 in 2024.
- According to Business Quant data, Treasury Shares over the past three periods registered $351616.0, $356116.0, and $356116.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 2.72 Mn |
| 10 | Enveric Biosciences | 5.58 Mn | -2.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 351,616.00 |
| Sep 30, 2024 | 351,616.00 |
| Jun 30, 2024 | 356,116.00 |
| Jun 30, 2024 | 356,116.00 |
| Mar 31, 2024 | 356,116.00 |
| Mar 31, 2024 | 356,116.00 |
| Sep 30, 2023 | 148,251.00 |
| Sep 30, 2023 | 148,251.00 |
| Jun 30, 2023 | 180,115.00 |
| Jun 30, 2023 | 180,115.00 |
| Mar 31, 2023 | 87,733.00 |
| Mar 31, 2023 | 87,733.00 |
| Sep 30, 2022 | 65,117.00 |
| Sep 30, 2022 | 65,117.00 |
| Jun 30, 2022 | 52,684.55 |
| Jun 30, 2022 | 52,684.55 |
| Mar 31, 2022 | 4.79 Mn |
| Mar 31, 2022 | 4.79 Mn |
| Dec 31, 2021 | 62,013.00 |
| Dec 31, 2021 | 62,013.00 |